23 results about "Mass screening" patented technology

The invention discloses application of sEVs membrane protein detection in breast cancer drug resistance early warning products, and belongs to the field of biomedicine. A plurality of breast cancer drug resistance associated sEVs membrane proteins are selected to form the combined marker, so that the detection accuracy can be effectively improved. By applying the antibody, the primer and the probe designed by the invention and combining the design of four-layer cascade amplification and multi-target conjoint analysis, four-round signal amplification can be completed, the limitation of a traditional single-target detection method is effectively broken through, the detection sensitivity is remarkably improved, the detection time is shortened, the detection cost is reduced, and the possibility is provided for clinical large-scale screening.

The application finds that SDF4 in a body fluid sample can become a marker for detecting cancer patients with good sensitivity and specificity. By using a reagent for specifically detecting SDF4, gastric cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, liposarcoma, bladder cancer, brain tumor, head and neck cancer, gallbladder cancer, ovarian cancer, tongue cancer, or uterine cancer can be detected. The measurement of SDF4 in a body fluid sample is a detection method capable of detecting various cancers by a single test, and can be used for large-scale screening of cancers. In addition, early-stage cancers can be detected with good sensitivity and specificity, so that cancers can be found and treated in an early stage.

The invention relates to the technical field of biomedical detection, in particular to a multi-dimensional tumor marker joint detection device and a using method thereof.The device comprises a sample processing module, a sequencing module, a marker extraction module, a feature fusion and detection module and a result output module, and 6 types of markers such as chromosome copy variation, microsatellite instability and the like are extracted respectively. The method comprises the following steps: collecting a body fluid sample to extract cfDNA, directly constructing a library without special treatment, obtaining effective data through whole genome sequencing, synchronously extracting six types of markers through each module of the device, optimizing an algorithm to adapt to low-depth data, inputting an integrated learning model to output a risk score, and finally outputting related information by a result output module. The method does not need special experimental treatment, realizes low-cost and high-accuracy joint detection, and meets the clinical large-scale screening requirements.

An artificial intelligence-based system and method for scalable screening of individuals for respiratory infection, such as COVID-19. The system is trained to distinguish distinct latent features of cough sounds produced by a COVID-19 infected person from cough sounds produced by patients suffering from any other respiratory infection or involuntary cough sounds produced by a healthy person. Cough sound samples from individuals can be remotely collected and evaluated by the system for likelihood of the COVID-19 infection. Additionally, images of affected body parts, biomarkers, metadata, and other respiratory sound samples can also be used for screening.

The application discloses a urine small extracellular vesicle PLA2R1 membrane protein detection method for distinguishing membranous nephropathy, and belongs to the technical field of biomedical detection. The detection method comprises the following steps: preparing an anti-CD63 antibody surface fixed plasmonic metasurface sensing chip to directly capture small extracellular vesicles in urine; preparing an anti-PLA2R1 antibody modified biofunctionalized gold nanoparticle complex to specifically combine with the PLA2R1 membrane protein on the surface of the small extracellular vesicles; detecting the reflection spectrum of the chip after antibody fixation and gold nanoparticle combination through a spectrometer with an integrated optical fiber probe; calculating the resonance wavelength shift amount; measuring the expression level of the PLA2R1 membrane protein; and realizing accurate distinction of healthy people, membranous nephropathy gray area and confirmed patients. The non-invasive detection method is simple in operation and rapid in detection, the sensitivity and the specificity are improved by means of the gold nanoparticle signal amplification effect, and is suitable for large-scale clinical screening and early diagnosis.

The invention discloses a bladder cancer early screening method based on plain-scan CT and MRI time sequence fusion, which realizes high-precision lesion recognition and positioning under the condition of low-dependence enhanced scanning through knowledge distillation and bimodal feature fusion. The method comprises the following steps: constructing a multi-modal data set including plain scanning, arteriovenous phase enhanced CT and MRI; a key frame sparse annotation and linear interpolation complementation strategy is adopted to reduce the annotation cost; performing preprocessing such as window level adjustment, normalization and zooming on the image; a CT / MRI recognition and positioning network is constructed, each sub-network comprises a 2D positioning branch and a 3D classification branch, and the characterization capability of plain scanning data is enhanced through a teacher-student knowledge distillation mechanism; and finally, integrating the bimodal information through a feature fusion module, and outputting a classification and positioning result. According to the method, time sequence consistency and modal consistency constraints are introduced, the recognition robustness of small focus and unclear boundary areas is improved, the manual film reading burden is remarkably reduced, the screening efficiency and safety are improved, and the method is suitable for early large-scale screening scenes of bladder cancer and has important clinical popularization value.

The invention discloses a test strip for detecting Alzheimer's disease and application thereof, the test strip adopts a colloidal gold-horseradish peroxidase compound labeling technology, the detection sensitivity is remarkably improved through enzyme signal amplification, and two key AD biomarkers p-Tau-181 and A beta 1-42 in blood can be synchronously detected. The test strip comprises a sample pad, a marking pad, a nitrocellulose membrane and absorbent paper, wherein the nitrocellulose membrane is provided with two detection lines (T1 and T2) for capturing p-Tau-181 and A beta1-42 respectively and a quality control line (C). The kit is high in sensitivity, rapid in detection, simple and convenient to operate, low in cost and suitable for primary medical treatment and large-scale screening scenes, and has important value in early diagnosis, popularization, prevention and control of the Alzheimer's disease.

The present application relates to the technical field of biological medicine, in particular to a lipid metabolite combination for early diagnosis of VKH and application thereof, by obtaining plasma samples of patients with initial acute stage (early stage) VKH syndrome and healthy controls, and constructing sample-full lipid quantitative expression matrix, screening differential lipids through PCA unsupervised analysis and OPLS-DA supervised model, further screening lipids with high diagnostic performance by using elastic net logistic regression model, finally obtaining a diagnostic marker combination composed of 25 lipid metabolites, solving the technical problems of existing VKH diagnosis technology, such as invasiveness, insufficient sensitivity and stability of protein marker detection, limited diagnostic efficiency, lack of systematicness and standardized process in lipidomics research, achieving the effect of non-invasive, efficient, high sensitivity and high specificity of early auxiliary diagnosis of VKH syndrome, and providing objective and reliable technical means for precise identification of atypical cases and large-scale clinical screening.

The invention belongs to the field of neurological disease diagnosis, and provides a plasma lipid marker for diagnosing Alzheimer's disease and application thereof, and the plasma lipid marker is selected from one or more of PA 16: 016: 0, PE O-18: 022: 4, PE P-16: 022: 4, TG 46: 4-FA18: 2, LPC 22: 4, ChE 22: 4, ChE 22: 0, ChE 20: 2, ChE 18: 0, ChE 16: 1 and ChE 20: 1. According to the present invention, the area under the curve (ROC) of the Alzheimer's disease subject diagnosed by the 11 plasma lipid markers is up to 1, and the Alzheimer's disease patient and the healthy subject can be accurately distinguished; detection can be completed through a venous blood collection method, a traditional cerebrospinal fluid collection method with higher trauma is replaced, and low-trauma and low-cost large-range crowd screening of the Alzheimer's disease is facilitated.

The invention discloses a pneumonia risk early warning method and system based on SNP site analysis. The method comprises the following steps: firstly, through comparative genomics analysis, respectively screening out two sets of core SNP site combinations which are obviously related to inseparable haemophilus influenzae (NTHI) pathogenic transformation and chronic disease progression; then, based on genotype data of the two sets of site combinations, a classification data set is independently constructed, and a machine learning algorithm is used to train and optimize to generate a health risk early warning model and a chronic risk assessment model. The trained model is utilized to analyze a to-be-tested sample, and the pathogenic risk probability and the chronic risk probability of the to-be-tested sample can be output respectively; the system comprises a data preprocessing and site screening module, a model construction module and an early warning analysis module. The method realizes staged and accurate quantitative evaluation of the NTHI pneumonia risk, and is suitable for large-scale screening and accurate prevention and control.

The invention belongs to the technical field of biological detection, and provides a multiplex digital PCR (polymerase chain reaction) primer probe group, a kit and a method for detecting GI type and GII type noroviruses. In order to cope with the current situations that the current digital PCR platform brands are numerous, reagent consumable boxes are incompatible and special kits are deficient, the kit developed by the invention can be used on various digital PCR platforms and shows excellent universality and stability. According to the method, synchronous detection, accurate typing and quantification of the norovirus in samples such as faeces and anal swabs are realized in one hole, high sensitivity, high specificity and good reproducibility are achieved, and an efficient and reliable solution is provided for early diagnosis and large-scale screening of the norovirus.

The application discloses a methylation marker combination for early breast cancer, a diagnostic product and application, and relates to the technical field of early breast cancer diagnosis. The methylation marker combination for early breast cancer comprises markers 1-13. The marker combination has the technical advantages of high sensitivity, high specificity, non-invasiveness and rapid detection for early breast cancer diagnosis, and can meet the demand of large-scale screening.

The application belongs to the field of neurological disease diagnosis, and provides a plasma lipid marker for diagnosing Alzheimer's disease and an application thereof. The plasma lipid marker is selected from one or more of PA 16:0_16:0, PE O-18:0_22:4, PE P-16:0_22:4, TG 46:4-FA18:2, LPC 22:4, ChE 22:4, ChE 22:0, ChE 20:2, ChE 18:0, ChE 16:1, ChE 20:1. The area under the curve (ROC) of 11 plasma lipid markers for diagnosing Alzheimer's disease is as high as 1, which can accurately distinguish Alzheimer's disease patients from healthy subjects; the detection can be completed by a method of collecting venous blood, instead of a traditional method of collecting cerebrospinal fluid with higher trauma, and is helpful to realize low-trauma, low-cost mass screening of Alzheimer's disease.

The application discloses application of sEVs membrane protein detection in a breast cancer drug resistance early warning product and belongs to the field of biomedicine. A plurality of sEVs membrane proteins associated with breast cancer drug resistance are selected to form a combined marker, which can effectively improve detection accuracy. Antibodies, primers and probes designed according to the application, combined with a "four-layer cascade amplification + multi-target joint analysis" design, can complete four rounds of signal amplification, effectively break through the limitations of traditional single-target detection methods, significantly improve detection sensitivity, shorten detection time and reduce detection cost, and provide a possibility for large-scale clinical screening.

The invention discloses an akabane disease virus monoclonal antibody with virus neutralizing activity and a colloidal gold immunochromatography test strip prepared from the akabane disease virus monoclonal antibody, and belongs to the technical field of biology. The monoclonal antibody is secreted by a hybridoma cell strain with the preservation number of CGMCC (China General Microbiological Culture Collection Center) NO.45859, and is named as 1H6. The monoclonal antibody provided by the invention can specifically recognize AKAV N protein and can neutralize akabane disease virus. A purified monoclonal antibody 1H6 is coupled with gold particles, a rabbit anti-AKAV polyclonal antibody is coated on an NC membrane to serve as a detection T line, a goat anti-mouse IgG antibody is coated on an NC membrane to serve as a quality control C line, the colloidal gold immunochromatography test strip for detecting akabane disease viruses is constructed, and the colloidal gold immunochromatography test strip can be used for detecting akabane disease virus antigens. The method has the advantages of no need of professionals, simplicity in operation, high detection sensitivity and simple and convenient operation requirements, can meet rapid and mass screening detection of grassroots enterprises and public institutions, and can also be used for detection analysis such as scientific research and the like.

The invention relates to the technical field of geochemical analysis, in particular to a zircon zirconium isotope detection method, which comprises the following steps: co-loading a zircon sample to be detected and a standard sample with a coherent growth structure; a femtosecond laser system integrated with laser-induced breakdown spectroscopy is used for performing real-time component sensing and dynamically adjusting laser parameters so as to realize intelligent denudation, generated aerosol is ionized by a series quadrupole rod inductively coupled plasma mass spectrometer, and interference is eliminated through two-stage mass screening and chemical reaction in a reaction tank; and a multi-receiver array is adopted to synchronously detect signals, and finally, multi-source data are fused and input into a pre-trained machine learning model for intelligent correction, so that the problems that polyatomic ion interference is serious, the matrix effect is remarkable, and high spatial resolution and analysis precision are difficult to consider at the same time are effectively solved. And high-precision and high-accuracy micro-area in-situ analysis of the zircon zirconium isotope is realized.

The present disclosure provides a use of a fusion protein EH containing a tuberculous allergen or a pharmaceutical composition containing the fusion protein EH in the preparation of a reagent or kit for immunological diagnosis of tuberculosis, auxiliary diagnosis of tuberculosis or screening of latent tuberculosis infection of Mycobacterium tuberculosis, the fusion protein EH containing ESAT6 and HspX. The recombinant allergen EH provided by the present disclosure has good specificity and high sensitivity, can be suitable for large-scale screening, and is a new generation of LTBI screening and diagnosis product technology with application and development potential. The recombinant allergen EH provided by the present disclosure has lower toxicity compared with EC, and is safer.

This invention discloses a qualitative test strip for HBV PreS1 antibody, its preparation method, and its applications, relating to the fields of virology, immunology, biodetection technology, and immunochromatographic analysis. Based on the principle of antigen-antibody specific recognition, the test strip achieves rapid detection of PreS1 antibodies in serum or plasma samples through the specific binding of PreS1 antigen and PreS1 antibody. It is assembled sequentially from a sample pad, a gold-labeled pad, a nitrocellulose membrane (NC membrane), and an absorbent pad. The gold-labeled pad is immobilized with colloidal gold-labeled anti-human IgG antibody as a gold probe. The NC membrane detection line (T line) is coated with HBV PreS1 antigen to capture PreS1 antibodies in the sample, and the NC membrane control line (C line) is coated with HB2 antibody to determine the effectiveness of the test strip's detection process. The test strip of this invention requires no complex instruments or equipment, the detection process is simple, rapid, and has good sensitivity and specificity, making it suitable for evaluating the immunization efficacy of hepatitis B vaccines and for large-scale screening.

The invention belongs to the technical field of atomic molecule physics and nanometer feasibility, and discloses a high-pass cluster mass selector based on a double-layer electrode and a selection method. A two-layer electrode structure is adopted, a mass threshold value is set through a pulsed electric field, high-general-type mass screening is achieved, and ions with the mass higher than the set mass are allowed to penetrate efficiently. The double-layer design significantly reduces the complexity of processing and assembling, and improves the uniformity of the electric field and the controllability of the fringing field. Meanwhile, the double-layer design structure has good adaptability to ion initial energy distribution, and stable screening performance can be kept under actual experiment conditions. The simplified scheme of the double-layer design not only can support the application of large-mass ion aggregation, wide-range mass measurement and the like, but also provides a feasible technical path for the implementation of a compact high-integration-level flight time system.

This invention discloses a specific binding protein for 25-OH-VD and its uses. The sequence of the specific binding protein TG-87 is shown in SEQ ID NO:1, and it has the ability to specifically bind to 25-OH-VD. This protein also exhibits good thermostability, which helps improve the storage stability and reliability of related diagnostic reagents, making it suitable for clinical testing and large-scale screening applications.

It was found that SDF4 in a body fluid sample can be a marker for detecting a cancer patient with good sensitivity and specificity. By using a reagent for specifically detecting the SDF4, it is possible to detect gastric cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, hepatic cancer, liposarcoma, bladder cancer, brain tumor, head and neck cancer, gallbladder cancer, ovarian cancer, tongue cancer, or uterine cancer. The measurement of the SDF4 in the body fluid sample is a test method capable of detecting various types of cancer with a single test, and can be used for mass screening for cancer. Further, it is capable of detecting even cancer of an early stage with good sensitivity and specificity, and thus is capable of detecting cancer at an early stage to start a treatment.

This invention relates to the field of biomedical detection technology, specifically to a multi-dimensional tumor marker joint detection device and its usage method. The device includes modules for sample processing, sequencing, marker extraction, feature fusion and detection, and result output. The marker extraction module contains six detection units, corresponding to the extraction of six types of markers, including chromosomal copy variation and microsatellite instability. Method: cfDNA is extracted from bodily fluid samples. A library is directly constructed without special processing. Valid data is obtained through whole-genome sequencing. The six types of markers are simultaneously extracted through various modules of the device, and the algorithm is optimized to adapt to low-depth data. The data are input into an ensemble learning model to output a risk score. Finally, the result output module outputs relevant information. This invention requires no special experimental processing, achieving low-cost, high-accuracy joint detection, and is suitable for large-scale clinical screening needs.

The invention discloses an osteoarthritis condition intelligent analysis method based on an ultrasonic image, and aims to solve the problems of time consumption and large error of manual analysis in existing diagnosis and difficulty in landing of the traditional technology. The method comprises the following steps: firstly, acquiring a joint ultrasonic image of a patient through ultrasonic equipment; gaussian filtering (the standard deviation is 0.5-1.0) is adopted for denoising, and histogram equalization (the gray level is 0-255) is adopted for enhancing the image; extracting quantitative characteristics such as joint gap width and cartilage thickness by using a Canny operator and morphological operation; and finally, inputting a pre-trained convolutional neural network model (the accuracy is greater than or equal to 92%), and outputting a normal, mild / moderate / severe inflammation four-stage grading result. The method realizes diagnosis automation, improves efficiency and accuracy, can quantitatively monitor illness conditions, depends on equipment popularization, is easy in algorithm implementation, and is suitable for medical scenes at all levels and large-scale screening.